---

Renal Tubular Acidosis (RTA) - Gold Medal Level (MD Pediatrics)

---

SECTION 1: PATHOPHYSIOLOGY (5 marks)

Background - Normal Acid-Base Homeostasis

1. Proximal tubule: Reabsorbs ~80% of filtered HCO3- (4500 mEq/day) via apical Na+/H+ exchanger (NHE-3) and basolateral Na+-HCO3- cotransporter (NBCe1); carbonic anhydrase II (cytoplasmic) and IV (luminal) are essential.
2. Distal nephron (cortical collecting duct): Secretes daily fixed acid load (~1 mEq/kg/day) via H+-ATPase (proton pump) and H+/K+-ATPase on type A intercalated cells; buffers excreted as NH4+ and titratable acid.

---

Type 1 - Classic Distal RTA (dRTA)

• Autosomal dominant: Missense mutation in AE1 gene (Cl-/HCO3- exchanger, Band 3 protein) - mistargeted to apical membrane; usually mild
• Autosomal recessive with sensorineural deafness (rdRTA1): Mutations in ATP6V1B1 encoding B1-subunit of H+-ATPase - H+-ATPase critical for cochlear/endolymph pH
• Autosomal recessive without deafness (rdRTA2): Mutations in ATP6V0a4
• Type 3 (mixed proximal + distal): Carbonic anhydrase II deficiency (CA2 gene) = Guibaud-Vainsel syndrome (osteopetrosis + cerebral calcification + mixed RTA)

• Loss of electrogenic H+ secretion → compensatory K+ secretion to maintain electronegativity in distal nephron
• Impaired H+/K+-ATPase (normally reabsorbs K+ in exchange for H+)
• Secondary hyperaldosteronism (stimulated by acidosis-induced ECF volume depletion)

• Chronic acidosis → mobilization of bone calcium → hypercalciuria
• Decreased tubular citrate reabsorption (citrate is an important inhibitor of calcium precipitation) → hypocitraturia
• Alkaline urine pH → calcium phosphate precipitation

---

Type 2 - Proximal RTA (pRTA)

1. Reduced proximal HCO3- reabsorption → HCO3- floods distal nephron → bicarbonaturia
2. Distal nephron becomes overwhelmed but can still acidify urine below pH 5.5 once serum HCO3- falls to a new steady-state level
3. New steady state reached at HCO3- ~15-18 mEq/L - acidosis is NOT progressive (unlike dRTA)
4. During bicarbonaturia: alkaline urine; once HCO3- falls to threshold: urine pH can be <5.5

• Isolated pRTA: Mutations in SLC4A4 gene encoding NBCe1 (basolateral Na+-HCO3- cotransporter) - autosomal recessive, associated with ocular abnormalities (glaucoma, band keratopathy, cataracts)
• Rare dominant form: Mutation in apical NHE-3

• Baseline: Mild hypokalemia from secondary hyperaldosteronism
• With NaHCO3 therapy: Massive increase in distal Na+ and HCO3- delivery → dramatic increase in renal K+ wasting. This is critical pediatric pearl - always add K+ supplementation when treating pRTA.

---

Type 4 - Hyperkalemic RTA (Generalized Distal Nephron Dysfunction)

1. Hyporeninemic hypoaldosteronism (most common in adults - diabetes + mild CKD)
2. Hypoaldosteronism (Addison's disease, bilateral adrenalectomy, heparin therapy)
3. Pseudohypoaldosteronism (PHA) type 1: Aldosterone resistance
   • Autosomal recessive (PHA1a): Loss-of-function mutations in ENaC subunits (α, β, or γ) - severe, multi-organ (kidney, lung, sweat glands)
   • Autosomal dominant (PHA1b): Mineralocorticoid receptor mutations - milder, renal limited
4. PHA type 2 / Gordon syndrome: WNK kinase pathway mutations → NaCl cotransporter overactivation → hyperkalemia, hypertension, acidosis
5. Voltage defect disorders: Obstructive uropathy, sickle cell disease, drugs (NSAIDs, ACE inhibitors, ARBs, calcineurin inhibitors, K+-sparing diuretics, trimethoprim, pentamidine)

---

Type 3 RTA (Mixed)

---

SECTION 2: DIAGNOSTIC APPROACH (5 marks)

Step-by-Step Framework

• Serum: Na+, K+, Cl-, HCO3-, BUN, creatinine, glucose
• Anion gap = Na+ - (Cl- + HCO3-); normal = 8-12 mEq/L
• Rule out: GI HCO3- loss (diarrhea), renal failure (GFR <40 mL/min), DKA, TPN

• UAG = Urine (Na+ + K+) - Urine Cl-
• UAG estimates urinary NH4+ (the predominant unmeasured cation)
• Positive UAG (>0 to +20) = reduced NH4+ excretion = renal cause (RTA) ← kidneys failing to excrete acid
• Negative UAG (<0) = adequate NH4+ excretion = extrarenal cause (diarrhea, fistula, alkali loss)
• Caveat: UAG is unreliable when urine Na+ <20 mEq/L (volume depletion); use urine osmolar gap [= measured Uosm - 2(UNa+UK) - U-urea/2.8 - U-glucose/18] instead; NH4+ ≈ 0.5 × urine osmolar gap

• Urine pH >5.5 (during spontaneous acidosis) → Type 1 (dRTA) or early in Type 2 (pRTA) (when HCO3- is still above threshold)
• Urine pH <5.5 → ability to acidify urine is intact → consider Type 2 (below threshold), Type 4, or extrarenal cause

• Urine pH >5.5 + positive UAG + low K+ → Distal RTA (Type 1)
• Urine pH >5.5 + positive UAG + high K+ → Type 4 / generalized tubular defect / ureteral obstruction
• Urine pH <5.5 + low K+ → do bicarbonate infusion → if FeHCO3- >15% → Proximal RTA (Type 2)
• Urine pH <5.5 + high K+ → Hypoaldosteronism / PHA / CKD / Gordon syndrome

---

Specific Confirmatory Tests

For Distal RTA (Type 1):

• Administer oral NaHCO3 to raise urine pH >7.5
• Normal: Urine pCO2 - Blood pCO2 >20 mmHg (H+ secretion generates CO2 as buffers are titrated)
• dRTA: U-B pCO2 <20 mmHg (classic secretory defect) or normal (backleak defect - hence useful for differentiating subtypes)

• NH4Cl 0.1 g/kg orally → normally urine pH falls to <5.3 within 4-6 hours
• dRTA: Urine pH remains >5.5 despite systemic acidosis
• Contraindicated in hepatic disease - use furosemide + fludrocortisone as alternative (safer, more convenient)

• Furosemide 40 mg + fludrocortisone 1 mg orally → maximizes distal Na+ delivery and aldosterone effect
• Normal: Urine pH <5.3 within 3 hours
• dRTA: Failure to acidify; Type 4: Also fails but due to different mechanism

For Proximal RTA (Type 2):

• Infuse NaHCO3 to normalize serum HCO3- (~24 mEq/L)
• FeHCO3- = (U-HCO3- × P-Cr) / (P-HCO3- × U-Cr) × 100
• FeHCO3- >15-20% = proximal RTA (massive bicarbonaturia when serum HCO3- is at normal level)
• FeHCO3- <5% = distal RTA (distal tubule can handle the HCO3-)
• During infusion: Urine pH becomes alkaline in pRTA (hallmark)
• Limitation: Worsens hypokalemia - monitor closely

• Urine glucose (with normal plasma glucose)
• Urine amino acids (generalized aminoaciduria)
• Urine phosphate (tubular maximum for phosphate/GFR = TmP/GFR - low in Fanconi)
• Urine uric acid (hypouricemia + uricosuria)
• Low-molecular-weight proteins (β2-microglobulin, retinol-binding protein)

For Type 4 RTA:

• Plasma aldosterone level (low in hypoaldosteronism, normal/high in PHA)
• Plasma renin activity (low in hyporeninemic hypoaldosteronism)
• Transtubular K+ gradient (TTKG) = (U-K+ / P-K+) / (U-osm / P-osm)
  • TTKG <5 in a hyperkalemic patient = impaired tubular K+ secretion (renal origin)
  • TTKG >7-10 = adequate collecting duct K+ secretion (non-renal hyperkalemia)
  • TTKG response to mineralocorticoid administration: if TTKG rises → hypoaldosteronism; if no rise → PHA (end-organ resistance)
• Fractional excretion of K+ (FEK+) <25% in hyperkalemia → renal K+ retention

Additional Investigations (Pediatric Workup):

---

Summary Comparison Table

---

SECTION 3: MANAGEMENT (5 marks)

General Principles

1. Treat the underlying cause where possible (e.g., cysteamine for cystinosis, discontinue offending drugs)
2. Alkali therapy is the cornerstone - replaces ongoing bicarbonate losses and corrects acidosis
3. Monitor serum electrolytes, urine calcium, renal function, growth velocity, and bone density
4. Goal: Serum HCO3- ≥20-22 mEq/L (children), normalize growth, prevent/treat nephrocalcinosis and bone disease

---

Type 1 - Distal RTA Management

• Children: 2-4 mEq/kg/day (up to 5 mEq/kg/day in infants)
• Adults: 1-2 mEq/kg/day NaHCO3

• Potassium citrate is preferred in dRTA because:
  1. Corrects hypokalemia simultaneously
  2. Increases urinary citrate → inhibits nephrocalcinosis/stone formation
  3. Citrate is metabolized to HCO3- in the liver
• Sodium bicarbonate can worsen hypokalemia initially (intracellular shift of K+ as pH corrects)
• Shohl's solution (sodium citrate + citric acid): Each 1 mL = 1 mEq base; useful in children
• K-citrate (Urocit-K): 5-10 mEq/tablet

• If severe hypokalemia with flaccid paralysis: IV potassium FIRST, then alkali (alkali alone will worsen hypokalemia, risking respiratory muscle paralysis)
• Aim serum K+ ≥3.0 mEq/L before starting alkali in acute setting

• Nephrocalcinosis: Adequate alkali + K-citrate (prevents progression; established deposits may not reverse)
• Rickets/osteomalacia: Correction of acidosis alone usually sufficient; Vitamin D/calcium supplementation if deficient
• Growth failure: Corrects with adequate alkali therapy (catch-up growth expected)
• Hearing loss (rdRTA1): Hearing aids / cochlear implant as needed - acidosis correction does not reverse deafness

---

Type 2 - Proximal RTA Management

• Children with isolated pRTA: 5-10 mEq/kg/day (may need up to 10-15 mEq/kg/day)
• Adults: Often needs only small doses; some cases of acquired pRTA resolve with treatment of cause

• Phosphate 25-50 mg/kg/day in divided doses (3-5 times daily)
• Add activated Vitamin D (calcitriol 0.25-0.5 mcg/day) to prevent secondary hyperparathyroidism from phosphate loading

• Induce mild volume contraction → stimulates proximal HCO3- reabsorption → less alkali required
• Used as adjunct, not primary therapy

---

Type 4 - Hyperkalemic RTA Management

• Dietary K+ restriction (<1 mEq/kg/day)
• Sodium bicarbonate (shifts K+ intracellularly + corrects acidosis)
• Loop diuretics (furosemide): First-line in many cases; corrects hyperkalemia and mild acidosis together
• Ion exchange resins (sodium/calcium polystyrene sulfonate, patiromer)
• Discontinue causative medications (NSAIDs, ACEi/ARBs, calcineurin inhibitors, K+-sparing diuretics)

• Fludrocortisone 0.1-0.2 mg/day orally
• Increases Na+ reabsorption via ENaC → creates electronegativity → promotes K+ and H+ secretion
• Effective in true hypoaldosteronism and hyporeninemic hypoaldosteronism
• Not effective in PHA (end-organ resistance)

• No response to fludrocortisone
• High-dose sodium supplementation (to overcome ENaC dysfunction)
• May improve with age (extrarenal manifestations - pulmonary involvement may be life-threatening in neonates)

• Milder; may respond partially to supraphysiologic fludrocortisone
• Often improves spontaneously with age

• Low-dose thiazide diuretics - highly effective (corrects the NaCl cotransporter overactivation)

• NaHCO3 0.5-1 mEq/kg/day - relatively small doses needed
• Acidosis often corrects with hyperkalemia treatment alone

---

Alkali Replacement Formulations (Key Table for Exams)

---

High-Yield Pediatric Pearls (Gold Medal Level)

1. dRTA most feared complication = nephrocalcinosis → renal failure; K-citrate (not NaHCO3) is preferred to prevent stone disease
2. pRTA treatment paradox: The more you treat pRTA, the more K+ is lost - always co-administer KCl
3. Acute severe dRTA with flaccid paralysis: IV K+ FIRST before any alkali
4. Cystinosis is the most common cause of Fanconi syndrome in children; diagnose with WBC cystine levels; treat with cysteamine
5. Type 3 RTA = osteopetrosis + brain calcifications + mixed RTA = CA2 gene deficiency (Guibaud-Vainsel)
6. rdRTA1 (ATP6V1B1): Always check audiogram - sensorineural deafness is present
7. Endemic dRTA (northeastern Thailand): H+/K+-ATPase abnormality
8. Growth failure in children with RTA is reliably corrected with adequate alkali therapy - catch-up growth is a major treatment endpoint
9. Amphotericin B causes dRTA by backleak mechanism (not secretory defect) → U-B pCO2 may be normal
10. Topiramate causes pRTA (carbonic anhydrase inhibitor) - affects 15-25% of patients on this anticonvulsant
11. UAG pitfall: Unreliable when urine Na+ <20 mEq/L; use urine osmolar gap instead
12. TTKG interpretation: TTKG <5 in a hyperkalemic patient = renal K+ retention = Type 4 RTA; if TTKG rises with fludrocortisone → hypoaldosteronism; if no rise → PHA

---

Recent Updates (PubMed 2022-2026)

• A 2023 review in Nature Reviews Nephrology (PMID 37016093) provides updated molecular pathophysiology of dRTA, emphasizing the role of H+-ATPase subunit mutations and genotype-phenotype correlations in hereditary forms - confirming that ATP6V1B1 mutations carry a greater risk of deafness and more severe hypokalemia than ATP6V0a4 mutations.
• Current consensus maintains that potassium citrate is preferred over sodium bicarbonate in dRTA for its dual benefit on hypokalemia and nephrocalcinosis prevention.
• Genetic testing panels (next-generation sequencing) are now the gold standard for confirming hereditary RTA in children, replacing solely clinical/biochemical classification.

---